The Company’s anticipated FY2023 revenue guidance range is confirmed between $90 million and $95 million, or growth of the commercial portfolio in the range of 13% and 19%, as compared to the 2022 fiscal year results.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on THTX:
- Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
- Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
- Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
- Theratechnologies receives Nasdaq non-compliance notification letter
- Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
